80 deals created $44.8 billion of market value for newly public US biotechs (Image: Genomics Law Report).
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
| Website: | www.allogene.com |
| Email: | Christine.Cassiano@allogene.com |
| Main Phone: | +1 650 457-2700 |
| Address: | 210 East Grand Avenue |
| State: | CA |
| City / Town: | South San Francisco |
| Country: | US |
| Postal Code: | 94080 |
| Exchange: | NGS |
| CEO: | David D. Chang |
| Employees: | 265 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
80 deals created $44.8 billion of market value for newly public US biotechs (Image: Genomics Law Report).
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
